Semaglutide

Discovery and Development

Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a 30-amino-acid hormone secreted by intestinal L-cells in response to food intake. It was developed by Novo Nordisk through systematic modification of the native GLP-1 sequence — most notably the addition of a C18 fatty-acid side chain at position 26, which binds serum albumin and extends the peptide's half-life from roughly two minutes (native GLP-1) to approximately 165 hours. That once-weekly pharmacokinetic profile is what made semaglutide clinically practical where earlier GLP-1 agonists required daily injection.

The FDA first approved semaglutide as Ozempic for type 2 diabetes in December 2017. A higher-dose formulation branded Wegovy was approved for chronic weight management in adults in June 2021, and an oral tablet form branded Rybelsus — the first orally bioavailable GLP-1 agonist — was approved in September 2019.

Mechanism of Action

Semaglutide activates the GLP-1 receptor, a G-protein-coupled receptor expressed on pancreatic beta cells, in the gastrointestinal tract, and in several regions of the central nervous system including the hypothalamus and brainstem. Its principal effects are:

• Glucose-dependent insulin secretion. Unlike sulfonylureas, semaglutide only triggers insulin release when blood glucose is elevated, which substantially reduces hypoglycemia risk as monotherapy.
• Glucagon suppression. Postprandial glucagon release from pancreatic alpha cells is reduced, lowering hepatic glucose output.
• Delayed gastric emptying. Food moves more slowly from stomach to duodenum, blunting postprandial glucose spikes and prolonging satiety.
• Central appetite regulation. Signaling at hypothalamic GLP-1 receptors reduces hunger and food reward, which accounts for most of the weight loss observed in clinical trials.

Clinical Evidence

The evidence base for semaglutide is exceptionally strong. The STEP program — a series of Phase 3 trials for weight management — demonstrated average weight reductions of roughly 15% of baseline body weight over 68 weeks at the 2.4 mg dose, substantially exceeding any prior pharmacological weight-loss agent. The SUSTAIN trials established glycemic efficacy in type 2 diabetes. The landmark SELECT cardiovascular outcomes trial (published 2023) enrolled over 17,000 patients with established cardiovascular disease and obesity but without diabetes, and reported a 20% reduction in major adverse cardiovascular events — the first weight-loss drug ever to demonstrate cardiovascular benefit.

More recent trials have extended the indications further: the FLOW trial showed kidney-protective effects in patients with type 2 diabetes and chronic kidney disease, and STEP-HFpEF demonstrated symptom improvement in heart failure with preserved ejection fraction.

Safety Profile and Boxed Warning

Gastrointestinal side effects — nausea, vomiting, diarrhea, constipation, and abdominal pain — are by far the most common and are typically dose-dependent and most pronounced during titration. Less common but clinically important concerns include pancreatitis, gallbladder disease (increased gallstone formation has been observed), and, more recently documented, reductions in muscle mass accompanying rapid weight loss.

The FDA label carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies. Personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2 are absolute contraindications. Whether the rodent findings translate to humans remains an active area of post-marketing surveillance.

Ecosystem and What Comes Next

Semaglutide's commercial success has reshaped the obesity and diabetes therapeutic landscape. It shares the market with tirzepatide (Eli Lilly's dual GLP-1/GIP agonist), and several next-generation candidates are in late-stage development — notably retatrutide, a triple GLP-1/GIP/glucagon agonist. For a broader view of where this class is heading, see our 2026 comparison of the three leading agents.

Semaglutide is by far the most rigorously studied peptide on this library — but also one of the most expensive and supply-constrained. Compounded versions have proliferated in response, raising their own regulatory and quality concerns that the FDA has addressed repeatedly through 2024 and 2025.